Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.
-
The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients
-
Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.
-
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...
-
As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.
-
Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology
-
BetaGlue Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
-
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs
"Our cells naturally become more mesenchymal over time, so PRP’s ability to potentially reverse this trend is of tremendous scientific interest"
-
MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for...
-
Berlin, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Tacalyx, a privately held biotech company focused on developing novel TACA (Tumour Associated Carbohydrate Antigens) cancer therapies, announces...